Clinical trials: Cancer, Advanced Solid Tumors
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with…
- Trial name
- NCT05975073
- Testing
- Anvumetostat, IDE397
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 53 people
- Sponsor
- Amgen
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not…
- Trial name
- NCT01147029
- Testing
- angiogenesis inhibitor GSAO, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Cancer Research UK
Locally Advanced Solid Tumor, Metastatic Solid Tumor
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT03284502
- Testing
- HM95573, cobimetinib, HM95573, cetuximab
- Where
- 9 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Patients With Advanced Solid Tumors
A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced…
- Trial name
- NCT05370755
- Testing
- ICP-189
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Solid Tumor
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
- Trial name
- NCT03987685
- Testing
- Oratopo
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Athenex, Inc.
Advanced Solid Tumors
A Study of HDM2024 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: Is the drug safe and tolerable ? Does the drug exhibit antitumor activity ?…
- Trial name
- NCT07539285
- Testing
- HDM2024
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02496208
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Pancreatic Cancer
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety…
- Trial name
- NCT05162118
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Zhejiang University
Melanoma Stage IV, Solid Tumor
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy.
- Trial name
- NCT06425926
- Testing
- GIM-531, Anti-PD-1 monoclonal antibody
- Where
- 11 sites in United States
- Volunteers
- 117 people
- Sponsor
- Georgiamune Inc
Advanced Solid Tumours
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
This Phase I study is primarily designed to evaluate the safety and tolerability of AZD2811 at increasing doses in patients with advanced solid tumours and for whom no standard of care exists.
- Trial name
- NCT02579226
- Testing
- AZD2811
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumors
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
- Trial name
- NTRK (NCT04010240)
- Testing
- No intervention (this is a retrospective cohort study)
- Where
- France
- Volunteers
- 3,820 people
- Sponsor
- Institut Bergonié
Neoplams
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity…
- Trial name
- NCT07644650
- Testing
- MST-168
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
- Trial name
- NCT06730750
- Testing
- BMS-986490, Bevacizumab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 360 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Advanced or Metastatic Solid Tumors
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
- Trial name
- NCT06389526
- Testing
- CHS-1000, Toripalimab
- Volunteers
- 48 people
- Sponsor
- Coherus Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.